ES2071770T3 - Nuevos compuestos. - Google Patents

Nuevos compuestos.

Info

Publication number
ES2071770T3
ES2071770T3 ES90306882T ES90306882T ES2071770T3 ES 2071770 T3 ES2071770 T3 ES 2071770T3 ES 90306882 T ES90306882 T ES 90306882T ES 90306882 T ES90306882 T ES 90306882T ES 2071770 T3 ES2071770 T3 ES 2071770T3
Authority
ES
Spain
Prior art keywords
new compounds
anchorage
gpiii
gpii
gpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90306882T
Other languages
English (en)
Inventor
Alex Bollen
Diane Gregoire
Michel Heinderyckx
Paul Jacobs
Marc Massaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Application granted granted Critical
Publication of ES2071770T3 publication Critical patent/ES2071770T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

SE PRESENTA UNA PROTEINA DE LAS GLICOPROTEINAS DEL VIRUS VARICELLA-ZOSTER QUE CONSTA DE UN GPI SIN ANCLAJE, UN GPII SIN ANCLAJE O UN GPIII SIN ANCLAJE.
ES90306882T 1989-06-27 1990-06-22 Nuevos compuestos. Expired - Lifetime ES2071770T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37177289A 1989-06-27 1989-06-27

Publications (1)

Publication Number Publication Date
ES2071770T3 true ES2071770T3 (es) 1995-07-01

Family

ID=23465352

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90306882T Expired - Lifetime ES2071770T3 (es) 1989-06-27 1990-06-22 Nuevos compuestos.

Country Status (15)

Country Link
EP (1) EP0405867B1 (es)
JP (1) JPH0349694A (es)
KR (1) KR0166585B1 (es)
AT (1) ATE119939T1 (es)
AU (1) AU625328B2 (es)
CA (1) CA2019845A1 (es)
CY (1) CY1933A (es)
DE (1) DE69017769T2 (es)
DK (1) DK0405867T3 (es)
ES (1) ES2071770T3 (es)
HK (1) HK1006468A1 (es)
IE (1) IE66516B1 (es)
NZ (1) NZ234222A (es)
PT (1) PT94479B (es)
ZA (1) ZA904915B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
US6180369B1 (en) 1990-10-04 2001-01-30 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
CA2139515C (en) * 1992-07-17 2008-12-23 Gary B. Calandra Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
GB9226768D0 (en) * 1992-12-23 1993-02-17 Smithkline Beecham Biolog Vaccines
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
KR970006484A (ko) * 1995-07-27 1997-02-21 수두 바이러스의 당단백질을 대량발현시키는 동물세포주
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
IL125440A (en) * 1996-02-09 2002-02-10 Smithkline Beecham Biolog Vaccines against the IE-63 gene product of the chickenpox virus
KR100434023B1 (ko) * 1996-02-29 2005-05-09 주식회사 엘지생명과학 수두바이러스의당단백질을대량발현시키는동물세포주
DE19757767A1 (de) 1997-12-23 1999-07-15 Dade Behring Marburg Gmbh Immunreaktive Bereiche des Glycoproteins gpII des Varicella-Zoster-Virus (VZV)
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
WO2018104313A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN112142829B (zh) * 2019-06-28 2022-02-22 怡道生物科技(苏州)有限公司 水痘-带状疱疹病毒gE蛋白突变体及其表达方法
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587991T2 (de) * 1984-04-06 1995-07-20 Chiron Corp Rekombinanter herpes simplex gb-gd impfstoff.
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (en) * 1985-08-01 1987-02-25 Merck & Co. Inc. Assay for varicella-zoster virus (VZV) antibodies
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
AU2083788A (en) * 1987-06-30 1989-01-30 Upjohn Company, The Virus proteins having reduced o-linked glycosylation

Also Published As

Publication number Publication date
AU5779290A (en) 1991-01-03
DE69017769T2 (de) 1995-07-13
AU625328B2 (en) 1992-07-09
ZA904915B (en) 1991-06-26
DK0405867T3 (da) 1995-05-22
HK1006468A1 (en) 1999-02-26
DE69017769D1 (de) 1995-04-20
KR910001060A (ko) 1991-01-30
JPH0349694A (ja) 1991-03-04
CA2019845A1 (en) 1990-12-27
CY1933A (en) 1990-06-22
IE66516B1 (en) 1996-01-10
PT94479B (pt) 1997-05-28
KR0166585B1 (ko) 1999-01-15
IE902297L (en) 1990-12-27
EP0405867B1 (en) 1995-03-15
IE902297A1 (en) 1991-01-16
NZ234222A (en) 1992-03-26
ATE119939T1 (de) 1995-04-15
PT94479A (pt) 1991-02-08
EP0405867A1 (en) 1991-01-02

Similar Documents

Publication Publication Date Title
ES2071770T3 (es) Nuevos compuestos.
DE69022246D1 (de) Detektion von hpv-transkripts.
DK0426652T3 (da) Fremgangsmåde til blegning af cellulose uden brug af klor
ES2139329T3 (es) Nuevas variantes de la proteina fluorescente verde, gfp.
ES2057191T5 (es) Metodo de produccion para una composicion que contiene proteinas.
DK164088A (da) Syntetiske peptidantigener til paavisning af hiv-1-infektion
DE69024523D1 (de) Integration von planaren, optischen Freiraum-Komponenten
DE69005172D1 (de) Zahnzemente.
DE69004685D1 (de) Substituierte alkylamidderivate von teicoplanin.
DE3581787D1 (de) Druckentlastende medizinische vorrichtung zur verhuetung von wundliegen.
DE69230224D1 (de) Potenzierung von nmda-antagonisten
AT386670B (de) Leuchte, insbesondere strassenleuchte
DK36988A (da) Ekspression af p.falciparum-circumsporozoitprotein af gaer
DE3888722D1 (de) Fotozelle, insbesondere zur Feststellung von UV-Strahlung.
DE59009396D1 (de) Optisches system zur abbildung des lichts von lichtquellen.
IT7819638A0 (it) Vite autofilettante nonche'procedimento per la sua fabbricazione e ganascia di cilindratura per l'attuazione del procedimento.
IT9019723A0 (it) Procedimento per la modificazione di copolimeri di acrilato
DE68926537T2 (de) Optische Sortierung von Gegenständen
DE69026008D1 (de) Gerät zur Beschaffung von Abstandsinformation von einem Objekt, mittels augenblicklicher Beleuchtung des Objekts durch einen Lichtstrahl
DE69002136D1 (de) Saccharidderivate von protocatechualdehyd.
MX9307998A (es) Proteina de virus de varicela-zoster, derivados de la misma y vacuna que la contiene.
ATE109124T1 (de) Verfahren zur enantiomerentrennung von benzopyranderivaten.
DE69008183D1 (de) Epoxidation von fluor-olefin-verbindungen.
DE69006964T2 (de) Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen.
FR2653980B1 (fr) Conteneur-distributeur, notamment de parfum.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 405867

Country of ref document: ES